Pharmacogenetic information in Swiss drug labels - a systematic analysis

被引：17
作者：
Jeiziner, C. [1 ]
Suter, K. [2 ]
Wernli, U. [1 ]
Barbarino, J. M. [3 ]
Gong, L. [3 ]
Whirl-Carrillo, M. [3 ]
Klein, T. E. [3 ,4 ]
Szucs, T. D. [2 ]
Hersberger, K. E. [1 ]
Meyer zu Schwabedissen, H. E. [5 ]
机构：
[1] Univ Basel, Dept Pharmaceut Sci, Pharmaceut Care Res Grp, CH-4001 Basel, Switzerland
[2] Univ Basel, European Ctr Pharmaceut Med, Fac Med, CH-4056 Basel, Switzerland
[3] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA
[4] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[5] Univ Basel, Dept Pharmaceut Sci, Biopharm, CH-4056 Basel, Switzerland
来源：
PHARMACOGENOMICS JOURNAL | 2021年 / 21卷 / 04期
关键词：
CONSORTIUM CPIC GUIDELINE; BIOMARKER INFORMATION; CYP2D6; VARIANTS; GENE; HYPERSENSITIVITY; POLYMORPHISMS; GENOTYPES; HLA; US;
D O I：
10.1038/s41397-020-00195-4
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Implementation of pharmacogenetics (PGx) and individualization of drug therapy is supposed to obviate adverse drug reactions or therapy failure. Health care professionals (HCPs) use drug labels (DLs) as reliable information about drugs. We analyzed the Swiss DLs to give an overview on the currently available PGx instructions. We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB. From 5979 hits, 2564 were classified as PGx-relevant affecting 167 substances. 55% (n = 93) were classified as "actionable PGx". Frequently, PGx information appeared in the pharmacokinetics section and in DLs of the anatomic group "nervous system". Unstandardized wording, appearance of PGx information in different sections and unclear instructions challenge HCPs to identify and interpret PGx information and translate it into practice. HCPs need harmonization and standardization of PGx information in DLs to personalize drug therapies and tailor pharmaceutical care.
引用
收藏
页码：423 / 434
页数：12
相关论文
共 45 条
  • [11] Pharmacogenomic information in drug labels: European Medicines Agency perspective
    Ehmann, F.
    Caneva, L.
    Prasad, K.
    Paulmichl, M.
    Maliepaard, M.
    Llerena, A.
    Ingelman-Sundberg, M.
    Papaluca-Amati, M.
    [J]. PHARMACOGENOMICS JOURNAL, 2015, 15 (03) : 201 - 210
  • [12] European Commission, 2009, GUID SUMM PROD CHAR
  • [13] Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: Prevalence of related drug use
    Frueh, Felix W.
    Amur, Shashi
    Mummaneni, Padmaja
    Epstein, Robert S.
    Aubert, Ronald E.
    DeLuca, Teresa M.
    Verbrugge, Robert R.
    Burckart, Gilbert J.
    Lesko, Lawrence J.
    [J]. PHARMACOTHERAPY, 2008, 28 (08): : 992 - 998
  • [14] Prediction of CYP2D6 phenotype from genotype across world populations
    Gaedigk, Andrea
    Sangkuhl, Katrin
    Whirl-Carrillo, Michelle
    Klein, Teri
    Leeder, J. Steven
    [J]. GENETICS IN MEDICINE, 2017, 19 (01) : 69 - 76
  • [15] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
    Goetz, Matthew P.
    Sangkuhl, Katrin
    Guchelaar, Henk-Jan
    Schwab, Matthias
    Province, Michael
    Whirl-Carrillo, Michelle
    Symmans, W. Fraser
    McLeod, Howard L.
    Ratain, Mark J.
    Zembutsu, Hitoshi
    Gaedigk, Andrea
    van Schaik, Ron H.
    Ingle, James N.
    Caudle, Kelly E.
    Klein, Teri E.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 770 - 777
  • [16] Pharmacogenetic information for patients on drug labels
    Haga, Susanne B.
    Mills, Rachel
    Moaddeb, Jivan
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 297 - 305
  • [17] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
    Hicks, J. K.
    Bishop, J. R.
    Sangkuhl, K.
    Mueller, D. J.
    Ji, Y.
    Leckband, S. G.
    Leeder, J. S.
    Graham, R. L.
    Chiulli, D. L.
    LLerena, A.
    Skaar, T. C.
    Scott, S. A.
    Stingl, J. C.
    Klein, T. E.
    Caudle, K. E.
    Gaedigk, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) : 127 - 134
  • [18] Holsboer-Trachsler E, 2010, SWISS MED FORUM, V10, P716
  • [19] HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions
    Ikeda, Hiroko
    Takahashi, Yukitoshi
    Yamazaki, Etsuko
    Fujiwara, Tateki
    Kaniwa, Nahoko
    Saito, Yoshiro
    Aihara, Michiko
    Kashiwagi, Mariko
    Muramatsu, Masaaki
    [J]. EPILEPSIA, 2010, 51 (02) : 297 - 300
  • [20] CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids
    Knisely, Mitchell R.
    Carpenter, Janet S.
    Draucker, Claire Burke
    Skaar, Todd
    Broome, Marion E.
    Holmes, Ann M.
    Von Ah, Diane
    [J]. APPLIED NURSING RESEARCH, 2017, 38 : 107 - 110
12345